Heptares Therapeutics Ltd Company Profile

22:10 EST 18th November 2017 | BioPortfolio

Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases.

We have established R&D collaborations with Shire, Takeda, AstraZeneca, Medimmune, and Novartis Option Fund, and have raised $40 million in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.

Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically undruggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.

Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, autism, anxiety & depression, chronic insomnia, addiction and diabetes.

Heptares was founded in 2007 to develop and commercialise pioneering research from the MRC Laboratory of Molecular Biology (Cambridge, UK) and the National Institute of Medical Research (London, UK). Heptares retains exclusive consultancies and active collaboration with MRC LMB and has rights to all IP generated from LMB relating to the application of the technology to GPCRs and other transmembrane proteins.


Broadwater Road
Welwyn Garden City


Phone: +44 (0)1707 358 628

News Articles [558 Associated News Articles listed on BioPortfolio]

PeptiDream, Heptares sign deal on GPCR-targeting drug studies

Heptares Therapeutics agreed to collaborate with PeptiDream to identify, develop and market drugs that target G protein-coupl -More- 

Heptares doses first subject in Alzheimer’s drug trial

London, UK-based Heptares Therapeutics says the first healthy subject has now been dosed with its first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase I clinical study.

Heptares launches new research collaboration with Tokyo-based university

Heptares Therapeutics, a wholly-owned subsidiary of Sosei Group, has launched a new research collaboration…

Heptares enters a research and drug discovery collaboration with Juntendo University

Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, announces the launch of a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan....

Heptares, Juntendo enter research and drug discovery collaboration

Heptares Therapeutics, a wholly-owned subsidiary of Sosei Group, announced the launch of a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan. The new coll...

Heptares, PeptiDream Partner on GPCR-Targeting Drugs for Inflammatory Diseases

Heptares Therapeutics and PeptiDream established a strategic collaboration to discover, develop and commercialize therapeutics targeting a jointly selected, undisclosed G protein-coupled receptor (GPC...

Heptares enters a Research and Drug Discovery Collaboration with New York University

Heptares Therapeutics announces the launch of a new research collaboration under its ORBIT initiative with New York University (NYU) School of Medicine. This new collaboration will support a multi-yea...

Heptares starts dosing in Phase I trial of Alzheimer’s drug

UK-based Heptares Therapeutics has started dosing subjects in a Phase I clinical trial of HTL0016878 being developed for the treatment of neurobehavioural symptoms in Alzheimer’s disease patients.

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1168 Associated Companies listed on BioPortfolio]

Heptares Therapeutics Ltd

Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. We have established R&D co...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Heptares Therapeutics Ltd" on BioPortfolio

We have published hundreds of Heptares Therapeutics Ltd news stories on BioPortfolio along with dozens of Heptares Therapeutics Ltd Clinical Trials and PubMed Articles about Heptares Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Heptares Therapeutics Ltd Companies in our database. You can also find out about relevant Heptares Therapeutics Ltd Drugs and Medications on this site too.

Quick Search

Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record